Metastatic Thyroid Cancer Study
How much iodine goes into cancer cells after thyroid-stimulating hormone therapy?
The standard treatment for thyroid cancer is radioactive iodine (RAI). But how much of the RAI goes into the cancer cells? During this study, doctors will assess a new imaging tool - 124I PET/CT- to evaluate how much iodine goes into the tumor. This study aims to compare how much iodine goes into cancer cells after two different methods of stimulation of RAI uptake. The imaging will be followed by therapy with RAI dose individualized to each patient, based on the tumor uptake measured by 124I PET/CT.
The NIDDK research team is seeking adult patients, age 18 and older, with thyroid cancer that has spread outside the thyroid – to the lymph nodes, lungs, or bones.
All tests and procedures are provided at no cost. Travel and lodging assistance may be provided.
For more information and enrollment, call the NIH Clinical Center Office of Patient Recruitment at 866-444-2214 (TTY users dial 7-1-1) or ccopr@nih.gov. Or go online. Refer to study #19-DK-0050.
Natural History Study of CADASIL
NHLBI researchers are looking for study participants with CADASIL as well as healthy volunteers for an observational research study to examine genetic and physical characteristics of the small vessel disease called CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy).
Contact the NIH Clinical Center Office of Patient Recruitment at 866-444-2214 (TTY users dial 7-1-1) or ccopr@nih.gov. Or go online. Refer to study #000413-H.